Posts in category All News
For a handful of equity and shine, investors open 4.3 m Demat a/cs (06-07-2024)
Rachel Reeves, Britain’s First Female Chancellor, Turns to Janet Yellen for Inspiration (06-07-2024)
Inside the Factory Turning Trash Into Olympic Podiums (06-07-2024)
Marksans Pharma- Can it be the next Pharma Biggie? (06-07-2024)
Should reflect in Q1
Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk? (06-07-2024)
Rahul Gandhi to be on Gujarat visit; to address party workers and meet Rajkot fire victims’ kin (06-07-2024)
India Ratings’ Devendra Pant on how water shortage can impact economic growth (06-07-2024)
Natco Pharma: Focusing On Complex Products (06-07-2024)
The ratings reaffirmation from ICRA considers Natco Pharma Limited’s healthy abbreviated new drug application (ANDA) portfolio in the complex generics space in the US market.
Based on the report, the positive aspects of Natco Pharma Limited are:
-
Healthy ANDA portfolio in complex generics space
-
Strong R&D capabilities
-
Notable market position in domestic oncology segment
-
Robust financial profile with low debt and strong liquidity
-
Strong manufacturing capabilities and backward integration into API manufacturing
-
Diversification into agrochemical segment
-
Substantial revenue contribution from gRevlimid and gCopaxone
-
Improvement in operating profit margins (OPM)
-
Strong cash and cash equivalents position
-
Negative net-debt position
And the negative aspects are:
-
High product concentration risk
-
High working capital intensity
-
Increasing competition in key markets
-
Exposure to regulatory risks and litigations
-
Warning letter from US FDA for Kothur facility
-
Dependence on few critical molecules
-
High inventory days
-
Increasing scrutiny by US FDA
-
Compliance costs and risks associated with regulatory requirements
-
Potential adverse outcomes on product litigations.
Personal Investment Disclosure: Invested. My comments are my personal opinions and may not reflect the company’s current situation.